Last reviewed 2026-04-20 · How we verify

CALCIUM GLYCEROPHOSPHATE

Calcium glycerophosphate is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it maintains a foothold in its therapeutic area. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Comparative Evaluation of the Role of Self-Adhesive Flowable Composite in Enhancing Sealant Retention Versus Conventional Pits and Fissure Sealant With and Without Fissurotomy in Permanent Molars (NA)
• Topical Dexamethasone, Ascorbic Acid, and BGP for Enhancing Implant Osseointegration (NA)
• A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E (PHASE1)
• A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP) (PHASE1)
• The Efficacy and Safety of Diluted Oral Phosphate Enema Versus Intravenous Sodium Glycerophosphate in The Treatment of Hypophosphatemia in ICU Patients (PHASE2, PHASE3)
• Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning
• Effect of Probiotic Toothpaste and Regular Toothpaste on Plaque Levels of Orthodontic Patients (NA)
• Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CALCIUM GLYCEROPHOSPHATE CI brief — competitive landscape report
• CALCIUM GLYCEROPHOSPHATE updates RSS · CI watch RSS